Avid Bioservices Inc (CDMO)

[Protector]

Another unworldly academic conclusion!

source: PPHM @ AACR 2017 - CT159 / 25 - IFN-? analysis in blood and tissue as a potential prognostic and/or predictive biomarker

Conclusions
Correlative approaches identified low peripheral low IFN-? at pretreatment as a biomarker of interest correlating with more favorable clinical outcomes and is consistent with the hypothesis that bavituximab may demonstrate more immunomodulatory effects in patients with “immune cold” tumors.

So we will have to explain it our-self.

Many scientists also hope that the concept of hot and cold tumors can be extended to a hot new class of immunotherapy drugs—“checkpoint inhibitors” designed to remove some of the immune system’s own self-control mechanisms that solid tumors put to grim use. So far, the new drugs tend to work best on cancers that tend to run hot on the immune scale, such as melanoma.

“Cold tumors are not very responsive to checkpoint inhibitors alone,” says Bender. “There’s just no immune engagement, so the inhibitor doesn’t take off the brakes.” [the non-responders in for instance anti-PD-L1]

That recognition is leading many labs—including labs at Novartis—to look at ways to activate the immune system in patients with cold tumors, by generating what is called a type 1 interferon response, before giving the patients a checkpoint inhibitor. Learn about a collaboration that is advancing this research.

source
So we PPHM shareholders KNOW that story of the immune system being blcked by PS and stimulated when we give Bavituximab. In other words, Bavituximab turns COLD tumor into HOT tumors which makes the new IO drugs work (=increases responders).


In IO (e.g. PD-1) one can say:
A cold tumor is one without PD-L1 expression and no T-cell infiltrate.


In normal language the conclusion could read like this:

Conclusions
Correlative approaches identified low peripheral low IFN-? at pretreatment as a biomarker of interest correlating with more favorable clinical outcomes and is consistent with the hypothesis that bavituximab may demonstrate more immunomodulatory effects in patients for which during there treatement the immune system doesn't activate sufficiently and therefore do not respond to the therapy (think IO).

So maybe now everybody can enjoy the conclusion, including PPHM shareholders who may now see that this is a WANTED RESULT and actually CONFIRMS what has always been claimed, BAVITUXIMAB activates the immune system. I wonder how many people knew what a cold tumor was in this context. So this is great news.